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Targeted therapy has remained elusive for most acutemyeloid leukemia patients. In this issue ofCancer Cell,
Stegmaier and colleagues identify SYK as a key mediator of the differentiation block seen in this disease.
Their data suggest that SYK inhibition may be an effective therapy for a significant proportion of AMLs.Despite significant advances in the treat-
ment of many hematopoietic malignan-
cies, the treatment of acute myeloid
leukemia (AML) remains a significant chal-
lenge, with current cytotoxic therapies
producing overall cure rates of less than
50%. From a biological perspective,
AML is known to be a heterogeneous
disease composed of different genetic
subtypes with distinct clinical features
and responses to contemporary thera-
pies. Recent results of detailed molecular
studies aimed at defining the underlying
pathogenesis of AML have yielded
important insights into a number of the
AML genetic subtypes. Moreover, these
studies have directly impacted the devel-
opment or application of new therapies
targeted to the underlying genetic alter-
ations or biological features of the
leukemic cells. These advances have
included the use of all-trans retinoic acid
and arsenic for the treatment of acute pro-
myelocytic leukemia, the recent develop-
ment and assessment of FLT3 inhibitors
for the treatment of patients with acti-
vating mutations in this receptor tyrosine
kinase, and the use of gemtuzumab, a cal-
icheamicin-conjugated anti-CD33 mono-
clonal antibody, for relapse. Despite these
and other advances, however, we still lack
a full understanding of the complement of
genetic and epigenetic alterations that
drive the malignant growth of AML blast.
As a result, the identification of key alter-
ations against which new therapeutic
agents can be developed remains
extremely difficult.
In this issue, an important way forward
is revealed through an innovative study
by Stegmaier and her colleagues, in which
they outline an experimental approach
that culminates in the unexpected finding
that inhibition of the spleen tyrosine
kinase, SYK, leads to differentiation and
impaired growth in a high percentage of270 Cancer Cell 16, October 6, 2009 ª2009AML cell lines and primary patient sam-
ples (Hahn et al., 2009). Thus, although
previous work suggested a role for this
kinase primarily in B and T cells, mast
cells, and macrophages, the present
results implicate SYK as a new rational
target for the treatment of AML.
These surprising results are based on
a series of studies by this group that
began back in 2004 with their develop-
ment of a novel gene expression-based
high-throughput small-molecule screen-
ing approach that used gene expression
profiling as a surrogate for a desired bio-
logical state (Stegmaier et al., 2004). In
their initial study, they demonstrated that
4,5-dianilinophthalimide (DAPH1) induced
differentiation of the myeloid leukemia cell
line HL60. Since DAPH1 was previously
shown to inhibit the kinase activity of the
epidermal growth factor receptor (EGFR),
they next tested the Food and Drug
Administration (FDA)-approved EGFR
inhibitor gefitinib (Iressa) and demon-
strated that it also was capable of inducing
differentiation and inhibiting cell viability in
several AML cell lines and, importantly, in
a small number of primary AML patient
samples (Stegmaier et al., 2005). These
studies were rapidly confirmed by others
and extended to a second FDA-approved
EGFR inhibitor, erlotinib (Tarceva), which
was shown to be slightly more potent
than gefitinib at inducing differentiation
and inhibiting cell viability (Boehrer et al.,
2008). In addition, two patients with AML
and concomitant non-small-cell lung
cancer were reported to have complete
remissions of their AML after receiving
erlotinib intended for treating their lung
cancer (Chan and Pilichowska, 2007; Pitini
et al., 2008). Since AML cells do not
express EGFR or the related receptor tyro-
sine kinase ERBB2, these data implicate
an as-yet-uncharacterized AML kinase
as the target of gefitinib/erlotinib. TheElsevier Inc.most highly expressed tyrosine kinases
in AML blasts include FLT3, KIT, INSR,
CSF1R, JAK1, FYN, CSK, HCK, and SYK
(Tomasson et al., 2008). However, with
the exception of FLT3, KIT, CSF1, and
JAK1, none of the other kinases are the
target of activating mutations in AML
(Loriaux et al., 2008; Tomasson et al.,
2008). Moreover, none of these kinases
bind in vitro to gefitinib or erlotinib (Fabian
et al., 2005). Thus, the specific AML
kinase(s) inhibited by gefitinib/erlotinib
remained unknown.
To explore the mechanism by which
EGFR kinase inhibitors induce differentia-
tion of myeloid leukemia cells, Stegmaier
used a combination of proteomic and
RNAi-based screening methodologies
(Figure 1). Using anti-phosphotyrosine
immunoaffinity purification of digested
cellular proteins, they found that after
gefitinib treatment of HL60 cells, the
SYK cytoplasmic tyrosine kinase was
among the most highly dephosphorylated
proteins detected, raising the possibility
that SYK was the elusive kinase. To
complement this approach, they then
performed a forward genetic screen on
HL60 cells with a kinome-targeted lentivi-
ral-based shRNA library, coupled with a
high-throughput gene expression-based
readout for differentiation. Remarkably,
this orthogonal approach identified a
shRNA against SYK as one of the best
inducers of differentiation. These initial
results were confirmed on other leukemia
cell lines and primary AML patient
samples through the use of additional
SYK shRNAs, as well as the SYK kinase
inhibitor R406. Moreover, SYK was found
to be highly expressed and phosphory-
lated in a significant subset of primary
AML samples, consistent with constitutive
activation. Thus, SYK appears to function
as a critical node within an as-yet-unchar-
acterized AML signaling pathway that
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PreviewsFigure 1. Orthogonal Approaches Identify SYK as a Target in AML
To define the off-target mechanism of gefitinib-induced myeloid leukemia cell differentiation, Stegmaier
and colleagues used a combination of proteomics and shRNA methods. To identify the proteins most
strongly dephosphorylated after gefitinib treatment, they enriched tyrosine-phosphorylated proteins
from control or gefitinib-treated HL60 leukemia cells with anti-phosphotyrosine antibodies (aPTy) and
analyzed them by LC-MS/MS. To complement this approach, they screened a kinome-enriched lentivi-
ral-based shRNA library for clones capable of inducing a differentiation-associated gene expression
signature. Remarkably, both approaches revealed that inhibition of SYK induced differentiation.contributes to the block in differentia-
tion and to enhanced cellular growth or
viability.
SYK together with zeta-activated pro-
tein of 70 kDa (ZAP-70) constitute a family
of nonreceptor tyrosine kinases that
contain two N-terminal Src homology 2
(SH2) domains and a C-terminal kinase
domain. SYK functions as a key mediator
of immune receptors signaling in inflam-
matory cells (B and T cells, mast cells,
macrophages, and neutrophils), and
aberrant signaling through this kinase
plays an important role in a range of auto-
immune diseases including asthma, rheu-
matoid arthritis, and allergic rhinitis. As
a result, the pharmaceutical industry has
dedicated considerable resources toward
developing SYK-specific inhibitors, and
these drugs are quickly moving through
clinical trials. Therefore, highly specific
SYK inhibitors are available for direct clin-
ical testing in AML.
As one contemplates clinical studies
using SYK inhibitors to treat AML patients,
there are several issues that will need to be
addressed. Foremost among these is
which patients will probably respond toSYK inhibition? In the present study, only
a limited number of primary AML samples
were analyzed, and they were heavily
biased toward de novo AMLs with normal
cytogenetics and/or FLT3 mutations. How
will other de novo AMLs, myelodysplasia-
related AMLs, or therapy-induced AMLs
respond? Also, with the importance of
leukemia stem cells in the pathogenesis
of AML, it will be important to determine
whether SYK inhibition has any effect on
this population of cells—since cures will
require their elimination. It will also be
important to determine the mechanisms
responsible for SYK activation in AML,
since to date SYK has not been identified
as a direct target of genetic lesions in this
disease. Understanding the genetic or
epigenetic alterations that lead to consti-
tutive SYK activation will be valuable in
identifying which patients have the best
chance to respond to SYK-targeted
therapy and whether targeting other
component of the signaling pathway may
be more appropriate in some patients.
Also, since differentiation agents never
produce durable cures on their own, the
development of murine AML models withCancer Cell 1activated SYK should serve as valuable
tools to help define the most effective
drug combinations to move into clinical
trials.
Although the identification of SYK as
a therapeutic target in AML is surprising,
previous studies have predicted that
mutations in signal transduction path-
ways would be an essential step in leuke-
mogenesis (Speck and Gilliland, 2002).
The problem has been identifying the
relevant targets. The approach used
by Stegmaier to integrate proteomics,
genome-wide expression profiling, and
high-throughput RNAi-based screening
should prove to be a valuable method
for identifying a range of new therapeutic
targets in AML and other cancers.
Coupling this approach with genome-
wide screens for mutation and epigenetic
alterations will provide a detailed road-
map for the development of true personal-
ized cancer therapy.
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